Sec. 214. Expanding investment by United States International Development Finance Corporation for vaccine manufacturing
229 words·~1 min read·
/bill/117/hr/3524/ih/section-214A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Development Finance Corporation is authorized to provide financing to entities in India and in other less developed countries to increase vaccine manufacturing capacity for the following purposes— manufacturing of Stringent Regulatory Authorization
(SRA)or World Health Organization
(WHO)Emergency Use Listing COVID–19 vaccines; manufacturing of SRA or WHO Emergency Use Listing therapeutics used to treat symptoms related to COVID–19; and manufacturing of critical medical supplies needed for preventing, detecting and treating COVID–19, including ventilators, personal protective equipment (PPE), oxygen, diagnostics, therapeutics and vaccines. Not later than 180 days after the date of the enactment of this Act, the Chief Executive Officer of the Development Finance Corporation, in coordination with the Secretary of State, shall provide a report to the appropriate congressional committees— outlining the countries where DFC financing could be most impactful for vaccine manufacturing and to achieve the goal of manufacturing 1 billion COVID–19 vaccines by 2022; a detailed explanation of the United States and partner country interests served by the United States providing support to such projects; a detailed description of any support provided by other United States allies and partners to expand the initiatives outlined in subsection (a); and a detailed description of any support provided by China in support of the initiatives outlined in subsection (a). The report required by subsection
(a)shall be submitted in unclassified form with a classified annex if necessary.